TAK

Takeda Pharmaceutical

Halal Rating :
Uncomfortable
Last Price $13.10 Last updated:
Market Cap $23.01b
7D Change -2.38%
1 Year Change -6.23%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NYSE
Next Earnings Date Oct. 31, 2024

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in gastroenterology; oncology; neuroscience; and rare diseases. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
June 30, 2024 $1.21t $1.05t $30.68b $59.69b 2.54% 5.70%
March 31, 2024 $1.21t $1.05t $34.81b $59.69b 2.88% 5.70%
Dec. 31, 2023 $1.11t $1.11t $21.79b $66.57b 1.96% 5.99%

Company Impact

Help us evaluate Takeda Pharmaceutical's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates